Some preclinical studies have shown that the combination of EGFR and VEGFR inhibitors has an enhanced effect on lung cancer cell lines with the potential to overcome primary or acquired resistance to EGFR inhibitors (61). This evidence concerns the gene EGFR and lung carcinoma.